Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis

{“title”:”Hidden Immune structures in arteries produce antibodies that accelerate atherosclerosis”,”excerpt”:”Researchers have identified artery tertiary lymphoid organs as sites that generate a high-affinity autoantibody against histone 2B, which accelerates atherosclerosis when transferred or induced by vaccination.”,”subject”:”The role of artery tertiary lymphoid organs in generating a pathogenic anti-histone 2B autoantibody that drives atherosclerosis”,”tags”:[“atherosclerosis”,”tertiary lymphoid organs”,”autoantibodies”,”B cells”,”germinal centers”,”histone 2B”,”single-cell transcriptomics”,”B cell receptor sequencing”,”autoimmunity”,”cardiovascular disease”],”html”:”For decades, atherosclerosis has been understood primarily as a disease of lipids: cholesterol accumulates in the walls of large arteries, provokes chronic inflammation, and gradually narrows the vessels that supply the heart and brain. Yet a growing body of evidence has pointed to a more complicated picture in which the immune system is not merely a bystander to plaque formation but an active participant. Now, a study published in Nature Cardiovascular Research adds a striking new layer to that story, showing that arteries themselves can host organized immune structures that manufacture precisely targeted autoantibodies capable of accelerating cardiovascular disease.

The structures in question are known as artery tertiary lymphoid organs, or ATLOs. Unlike the classical lymph nodes and spleen, which develop during embryogenesis and serve the entire body, tertiary lymphoid organs arise postnatally in response to chronic inflammation at affected tissues. In atherosclerosis, they form in the adventitia, the outermost layer of the arterial wall, adjacent to plaques rich in immune cells. Previous work had established that these structures contain germinal centers, the specialized microenvironments where B cells proliferate, mutate their antibody genes, and undergo selection for increasingly potent antigen binding. What remained unknown was what these germinal centers were actually targeting, and whether the antibodies they produced mattered for disease.

To answer those questions, the research team, led by Zihao Zhang, Yue Zhang, Shu Ran, Ying Wang and colleagues, combined single-cell transcriptomic profiling with B cell receptor sequencing of germinal center B cells harvested from artery tertiary lymphoid organs. Single-cell transcriptomics allows researchers to capture the complete gene expression program of individual cells, revealing their identity, activation state, and developmental trajectory. B cell receptor sequencing, meanwhile, reads out the rearranged antibody genes carried by each B cell, providing a molecular fingerprint of the antigen-binding receptor that defines the cell’s specificity. By layering these two datasets on top of one another, the investigators could reconstruct, at unprecedented resolution, the population of B cells being educated within the arterial wall itself.

The analysis revealed a clonally expanded population of autoreactive B cells within the ATLO germinal centers, indicating that these cells had undergone the canonical process of somatic hypermutation and antigen-driven selection that normally refines antibody responses during infection or vaccination. From this population, the team cloned a monoclonal antibody, designated A6, and demonstrated that it binds with high affinity to histone 2B, or H2B, one of the core histone proteins around which DNA is wrapped in every cell nucleus. Histones are potent immunological stimuli, well known to activate innate immune pathways, but the identification of a germinal center-derived, high-affinity antibody specific for H2B within the artery wall was unexpected and mechanistically significant.

The pathogenic relevance of the finding was established through two complementary lines of experimentation. First, the researchers tested H2B vaccination: when animals were immunized with histone 2B, the resulting immune response markedly accelerated the progression of atherosclerosis, confirming that a targeted anti-H2B response is sufficient to worsen disease. Second, and more directly, the team performed adoptive transfer of the anti-H2B A6 monoclonal antibody itself. Simply delivering the purified antibody into circulation was enough to significantly speed plaque development, demonstrating that the antibody is not merely a marker of the disease process but an active driver of it.

These results carry substantial mechanistic weight because they close a causal loop. Earlier studies had documented that tertiary lymphoid organs appear in the arterial adventitia as atherosclerosis advances, and that their germinal centers become more prominent with disease severity. But correlation is not causation, and it remained possible that the local immune structures were protective, attempting to contain plaque inflammation, or merely incidental. By identifying a specific autoantibody-autoantigen pair encoded within these structures and showing that the antibody accelerates disease when transferred, the study establishes that ATLOs are not passive observers but productive factories of pathogenic humoral immunity.

The technical achievement underlying the discovery deserves emphasis. Germinal center B cells are notoriously difficult to study because they are short-lived, rapidly dividing, and spatially restricted within organized lymphoid tissue. Extracting them from the arterial wall, dissociating the tissue into single cells while preserving RNA quality, and obtaining paired heavy- and light-chain B cell receptor sequences from each cell requires meticulous single-cell handling. The successful cloning of a functional monoclonal antibody from this dataset, one that retains its specificity and pathogenic activity when expressed recombinantly, validates the entire pipeline and opens the door to systematically cataloging the full repertoire of antigens targeted within atherosclerotic ATLOs.

The identification of H2B as the target antigen also connects atherosclerosis to a broader theme in autoimmunity. Anti-histone antibodies are hallmarks of several systemic autoimmune diseases, most notably drug-induced lupus, where they bind nuclear components released by dying cells. In atherosclerotic plaques, cell death is abundant: foam cells undergo apoptosis, necrotic cores accumulate, and nuclear debris is released into the plaque microenvironment. It is plausible that this ongoing cell death provides a continuous supply of histone antigen, which drains to the adjacent adventitial lymphoid structures and drives the affinity maturation of autoreactive B cells. The new findings suggest that atherosclerosis may therefore share fundamental immunological machinery with classical autoimmune diseases, a concept that reframes how the field thinks about cardiovascular inflammation.

Therapeutically, the work suggests several possible avenues, though the researchers are careful to note that translation from experimental models to human patients will require further validation. If comparable anti-H2B responses are confirmed in human atherosclerotic arteries, the autoantibody could serve as a biomarker for identifying patients whose disease is driven by autoreactive immunity. More ambitiously, the pathways that organize and sustain artery tertiary lymphoid organs, including the lymphotoxin and chemokine networks that recruit and retain lymphocytes in the vessel wall, could become targets for interventions designed to quiet local antibody production without globally suppressing protective immunity. Given that atherosclerosis remains the leading cause of death worldwide despite aggressive lipid-lowering therapy, any mechanism that explains residual cardiovascular risk in patients is of enormous clinical interest.

The study also raises fundamental questions about how immune tolerance breaks down inside the artery. Germinal centers normally enforce stringent selection against self-reactive B cells, yet the ATLO germinal centers clearly nurtured a high-affinity autoreactive clone to maturity. Understanding why the arterial environment licenses this breach, whether through the character of the antigens presented, the cytokine milieu, or the absence of regulatory cell networks found in conventional lymphoid tissue, may reveal general principles applicable to other chronic inflammatory diseases in which tertiary lymphoid structures arise, from rheumatoid arthritis to organ transplant rejection. For now, the demonstration that a single cloned antibody targeting a nuclear protein can measurably accelerate the arterial disease that kills more people than any other stands as a vivid reminder that the immune system, in the wrong context, can be as dangerous as any traditional risk factor.

The adventitia, where these lymphoid structures take root, has long been treated as a largely passive scaffold of collagen, vasa vasorum, and resident fibroblasts. The demonstration that it can host affinity-matured humoral responses repositions this outer arterial layer as an immunologically active compartment. It also helps explain earlier observations that immune-cell clusters in the adventitia expand in parallel with plaque burden and that lymphatic vessels draining the arterial wall become more prominent as disease advances, providing a plausible route by which plaque-derived antigens reach the local immune structures.

Histone 2B belongs to a family of proteins that are normally sequestered inside the nucleus, where they package DNA into nucleosomes. When cells die, particularly through the inflammatory forms of cell death common in plaques, histones can escape into the extracellular space, where they act as damage-associated molecular patterns that stimulate innate receptors. The new work shows that this same nuclear material can also serve as a target for affinity-matured adaptive responses, linking innate danger signaling and autoreactive antibody production within a single tissue site.

The adoptive transfer result is especially informative, because it separates the antibody itself from the cells that produce it. Accelerated plaque development following antibody delivery alone indicates that circulating anti-H2B immunoglobulin is sufficient to promote disease, pointing future mechanistic studies toward how the antibody engages antigens within the vessel wall and what effector pathways it recruits once bound.

Subject of Research: Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis

Article Title: Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis

Article References: Zhang, C., Zhang, X., Ran, Y., Wang, Z., Li, L., Wang, S., Zheng, J., Zhang, Y., Sun, T., Li, Y., Lu, S., Hong, M., Ma, Z., Steffens, S., Hristov, M., Blanchet, X., Zhu, J., Dou, X., Deng, X., … Yin, C. (2026). Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody−autoantigen pair in atherosclerosis. Nature Cardiovascular Research, 5(9), 869-890. https://doi.org/10.1038/s44161-026-00864-w

Image Credits: AI Generated

DOI: 10.1038/s44161-026-00864-w

Keywords: Artery, tertiary, lymphoid, organs, encode, pathogenic, high-affinity, autoantibody, autoantigen, pair, atherosclerosis, scientific research